Pulmonary Function Testing (PFT) is an indispensable tool in the diagnosis, monitoring, and management of respiratory diseases. However, the complexity of the test often poses interpretative challenges for healthcare professionals. This article aims to demystify the intricacies of PFT interpretation.
The primary components of PFT include spirometry, lung volumes, and diffusion capacity. Spirometry measures the flow and volume of air that can be inhaled or exhaled, providing key insights into obstructive or restrictive lung diseases. Lung volumes help evaluate the extent of air trapping, while diffusion capacity assesses the gas exchange at the alveolar-capillary level.
Spirometry results are interpreted based on the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC). A reduced FEV1/FVC ratio indicates obstructive lung disease, while a normal or increased ratio with reduced volumes suggests restrictive lung disease.
Increased lung volumes, particularly residual volume, suggest air trapping common in obstructive diseases. Reduced diffusion capacity, on the other hand, may indicate interstitial lung disease, pulmonary vascular disease, or emphysema.
Interpreting PFTs requires a comprehensive approach, integrating findings from all components. For instance, a reduced FEV1/FVC ratio, increased lung volumes, and reduced diffusion capacity may suggest an obstructive disease with emphysema.
Understanding the nuances of PFT interpretation is critical for accurate diagnosis and management of respiratory diseases. While complex, a systematic approach to interpretation can help healthcare professionals effectively utilize this valuable tool. Continued education and practice are key to mastering PFT interpretation.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation